V. Foos

1.5k total citations
50 papers, 1.1k citations indexed

About

V. Foos is a scholar working on Endocrinology, Diabetes and Metabolism, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, V. Foos has authored 50 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Endocrinology, Diabetes and Metabolism, 20 papers in Economics and Econometrics and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in V. Foos's work include Diabetes Treatment and Management (31 papers), Diabetes Management and Research (24 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). V. Foos is often cited by papers focused on Diabetes Treatment and Management (31 papers), Diabetes Management and Research (24 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). V. Foos collaborates with scholars based in United Kingdom, United States and Denmark. V. Foos's co-authors include Andrew Palmer, William J. Valentine, Stéphane Roze, Morten Lammert, Michael E. Minshall, Phil McEwan, Giatgen A. Spinas, David Grant, James L. Palmer and Mark Lamotte and has published in prestigious journals such as Diabetes, Diabetic Medicine and Diabetes Obesity and Metabolism.

In The Last Decade

V. Foos

43 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Foos United Kingdom 14 948 207 203 165 161 50 1.1k
Jan Stålhammar Sweden 16 251 0.3× 67 0.3× 92 0.5× 58 0.4× 57 0.4× 36 580
Jedidiah I Morton Australia 12 268 0.3× 67 0.3× 116 0.6× 39 0.2× 49 0.3× 58 460
Anat Fisher Canada 11 186 0.2× 49 0.2× 85 0.4× 65 0.4× 35 0.2× 32 451
Stefania Saragoni Italy 11 181 0.2× 105 0.5× 138 0.7× 45 0.3× 18 0.1× 35 542
Laney K. Jones United States 15 77 0.1× 239 1.2× 326 1.6× 30 0.2× 153 1.0× 60 668
Shengsheng Yu United States 12 166 0.2× 45 0.2× 60 0.3× 47 0.3× 27 0.2× 21 404
P McEwan United Kingdom 9 159 0.2× 103 0.5× 60 0.3× 49 0.3× 18 0.1× 38 447
Gunar Stemer Austria 10 202 0.2× 49 0.2× 128 0.6× 29 0.2× 11 0.1× 22 475
Roberta Picariello Italy 11 212 0.2× 44 0.2× 57 0.3× 38 0.2× 33 0.2× 24 379
Mark Rutkowski United States 14 90 0.1× 33 0.2× 57 0.3× 109 0.7× 47 0.3× 18 561

Countries citing papers authored by V. Foos

Since Specialization
Citations

This map shows the geographic impact of V. Foos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Foos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Foos more than expected).

Fields of papers citing papers by V. Foos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Foos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Foos. The network helps show where V. Foos may publish in the future.

Co-authorship network of co-authors of V. Foos

This figure shows the co-authorship network connecting the top 25 collaborators of V. Foos. A scholar is included among the top collaborators of V. Foos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Foos. V. Foos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McEwan, Phil, V. Foos, Geraint Roberts, et al.. (2025). Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model. Diabetes Obesity and Metabolism. 27(4). 1752–1761. 1 indexed citations
2.
McEwan, Phil, Martin Bøg, Mads Faurby, et al.. (2025). Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes. Journal of Medical Economics. 28(1). 268–278. 5 indexed citations
3.
Nigris, Enrico De, Phil McEwan, Jonathan Marshall, Ulf Holmgren, & V. Foos. (2022). POSB65 Economic Burden of COPD in the United Kingdom (2021–2040) Estimated with the COPD Health Outcome Policy and Intervention (CHOPIN) Model. Value in Health. 25(1). S72–S73. 3 indexed citations
4.
Foos, V., Phil McEwan, Ulf Holmgren, et al.. (2021). Projections of 10-year mortality in patients with COPD in the UK using the CHOPIN policy model. PA1012–PA1012. 3 indexed citations
5.
Foos, V., et al.. (2018). PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETES. Value in Health. 21. S138–S138. 1 indexed citations
6.
Lamotte, Michel, et al.. (2018). PDB76 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO LIRAGLUTIDE BASED ON CARDIOVASCULAR OUTCOME TRIALS. Value in Health. 21. S131–S131. 1 indexed citations
7.
Foos, V., Phil McEwan, & Mark Lamotte. (2016). Implications of Introducing Patient Heterogeneity in Cost Effectiveness Modeling. Value in Health. 19(7). A371–A371. 1 indexed citations
8.
Foos, V., et al.. (2016). COMPARING DIRECT AND INDIRECT COSTS OF TYPE 2 DIABETES ACROSS THREE AGE RANGES IN THE UNITED STATES. Value in Health. 19(3). A87–A87. 1 indexed citations
9.
Foos, V., Phil McEwan, Marc Evans, & Päivi M. Paldánius. (2015). The Role of Patient Level Data In Assessing Health Economic Value: A Case Study Using Edge and The Core Diabetes Model. Value in Health. 18(7). A702–A702. 1 indexed citations
10.
11.
12.
Evans, Marc, Phil McEwan, & V. Foos. (2014). Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation. Journal of Medical Economics. 18(2). 96–105. 25 indexed citations
13.
McEwan, Phil, V. Foos, David Grant, et al.. (2013). Predicting the Frequency of Severe and Non-Severe Hypoglycaemia in Insulin Treated Type-2 Diabetes Subjects. Value in Health. 16(7). A435–A435. 3 indexed citations
14.
McEwan, Phil, et al.. (2013). Drivers Of Cost-Effectiveness In Type-2 Diabetes Mellitus. Value in Health. 16(3). A165–A165.
15.
16.
17.
Foos, V., James L. Palmer, David Grant, et al.. (2012). PRM58 Long-Term Validation of the IMS CORE Diabetes Model in Type 1 and Type 2 Diabetes. Value in Health. 15(7). A470–A470. 10 indexed citations
18.
Valentine, William J., Andrew Palmer, Michael Brändle, et al.. (2007). PROactive 06: cost‐effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabetic Medicine. 24(9). 982–1002. 25 indexed citations
19.
Valentine, William J., Andrew Palmer, Morten Lammert, et al.. (2005). Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Current Medical Research and Opinion. 21(12). 2063–2071. 21 indexed citations
20.
Minshall, Michael E., Stéphane Roze, Andrew Palmer, et al.. (2005). Treating diabetes to accepted standards of care: A 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clinical Therapeutics. 27(6). 940–950. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Stålhammar Breakdown of academic impact, for papers by Jedidiah I Morton Breakdown of academic impact, for papers by Anat Fisher Breakdown of academic impact, for papers by Stefania Saragoni Breakdown of academic impact, for papers by Laney K. Jones Breakdown of academic impact, for papers by Shengsheng Yu Breakdown of academic impact, for papers by P McEwan Breakdown of academic impact, for papers by Gunar Stemer Breakdown of academic impact, for papers by Roberta Picariello Breakdown of academic impact, for papers by Mark Rutkowski
Rankless by CCL
2026